Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Mar;23(2):73-80.
doi: 10.1023/a:1022541009662.

Insights into the mitochondrial signaling pathway: what lessons for chemotherapy?

Affiliations
Review

Insights into the mitochondrial signaling pathway: what lessons for chemotherapy?

Catherine Brenner et al. J Clin Immunol. 2003 Mar.

Abstract

Mitochondria are potent integrators/coordinators of apoptosis signaling pathways. Indeed, under physiological conditions, the initiation of apoptosis leads to the accumulation of second messengers that converge on mitochondria. In response, these organelles undergo a membrane permeabilization, presumably due to the opening of protein channels, culminating in the release of proapoptotic proteins into the cytosol. Under pathological conditions, a failure of mitochondrial membrane permeabilization (MMP) can result in an inhibition of apoptosis and enhanced resistance to chemotherapy. Several non-mutually exclusive mechanisms may account for a defect in the execution or regulation of MMP. These include (i) alterations in gene transcription, (ii) gene mutations resulting in protein inactivation, and (iii) defects of intracellular localization. This may concern structural proteins of the permeability transition pore complex, as well as MMP regulatory proteins, such as Bax/Bcl-2 family members, p53, and cyclophilin D. Analysis of these mechanisms should improve our understanding of the basic function of mitochondria in apoptosis and help elaborate new strategies to correct MMP failure from a therapeutic perspective.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Oncogene. 2000 Mar 30;19(14):1735-43 - PubMed
    1. J Exp Med. 1996 Oct 1;184(4):1331-41 - PubMed
    1. Nat Rev Cancer. 2001 Dec;1(3):233-40 - PubMed
    1. Cell. 1996 Jul 12;86(1):147-57 - PubMed
    1. J Exp Med. 1995 Aug 1;182(2):367-77 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources